title: Changes in plasma levels of vasoactive peptides during standard bicarbonate hemodialysis.
abstract: During bicarbonate hemodialysis, there is an increase in peripheral vascular resistance of nonadrenergic origin, counteracting the hypotensive effect of fluid removal during the course of the dialysis. In this study, the plasma levels of vasoactive regulatory peptides, noradrenaline and renin, were investigated in 11 patients with chronic renal failure during standard bicarbonate hemodialysis (STHD) for 270 min. As regards vasoconstrictors, an increase in gamma 2-melanocyte-stimulating hormone (gamma 2-MSH), neuropeptide Y (NPY) and plasma renin activity (PRA) occurred. However, arginine vasopressin and noradrenaline were unchanged. With respect to vasodilators, calcitonin gene-related peptide was not changed. An initial increase in beta-endorphin (beta-END) occurred, followed by a decrease during the remaining part of the treatment. Motilin decreased during the first part of the treatment but increased to the baseline level during the latter part. An increase in substance P was observed while vasoactive intestinal peptide decreased. We conclude that an increase in vasoconstricting substances (gamma 2-MSH, NPY, PRA) occurs during STHD, probably owing to the decrease in plasma volume. With the exception of beta-END, the changes in vasodilators were fairly small. The data suggest that vasoactive substances might participate in the hemodynamic response to hemodialysis.
authors.affiliation: Department of Nephrology, University Hospital, Lund, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Hegbrant
authors.forename: H
authors.initials: H
authors.lastname: Thysell
authors.forename: L
authors.initials: L
authors.lastname: Mårtensson
authors.forename: R
authors.initials: R
authors.lastname: Ekman
authors.forename: U
authors.initials: U
authors.lastname: Boberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001127:Arginine Vasopressin / Q000097:blood; D001639:Bicarbonates; D015740:Calcitonin Gene-Related Peptide / Q000097:blood; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000097:blood; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood; D009479:Neuropeptides / Q000097:blood*; D009638:Norepinephrine / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D012083:Renin / Q000097:blood; D001615:beta-Endorphin / Q000097:blood
chemical_list: D001639:Bicarbonates; D009478:Neuropeptide Y; D009479:Neuropeptides; D001127:Arginine Vasopressin; D001615:beta-Endorphin; D009074:Melanocyte-Stimulating Hormones; D012083:Renin; D015740:Calcitonin Gene-Related Peptide; D009638:Norepinephrine